CIK细胞联合化疗在转移性乳腺癌患者中的疗效观察及安全性研究  

Efficacy and Safety of CIK Cells Combined With Chemotherapy in Metastatic Breast Cancer

作　　者：秦亚光[1] 张孟伟[1] 王亚秋[1] 

机构地区：[1]河南大学淮河医院肿瘤内科,开封475000

出　　处：《中国继续医学教育》2016年第8期172-173,共2页China Continuing Medical Education

摘　　要：目的研究CIK细胞联合化疗,在转移性乳腺癌患者中的临床疗效及安全性,为临床提供依据。方法选取2015年1月~2016年2月医院诊治的90例转移性乳腺癌患者资料进行分析,依据治疗措施分为对照组和观察组,各45例。对照组采用单一化疗治疗,观察组在对照组基础上联合CIK细胞治疗,比较两组临床疗效。结果观察组治疗疗效率为60.00%,临床获益率为88.89%,高于对照组治疗疗效率20.00%,临床获益率66.67%,差异具有统计学意义（P〈0.05）。观察组发生率为35.56%,低于对照组的51.11%,差异具有统计学意义（P〈0.05）。结论与单一化疗相比,转移性乳腺癌患者采用CIK细胞联合化疗治疗效果理想,药物安全性相对较高。Objective To study the clinical efficacy and safety of CIK cells combined with chemotherapy in patients with metastatic breast cancer, and to provide the basis for clinical treatment. Methods Selected and analyzed 90 patients with metastatic breast cancer who were treated in hospital from January 2015 to February and divided into two groups： the control group and the observation group, each of 45 cases. The control group was treated with single chemotherapy treatment, observation group was treated with CIK cell treatment, and the clinical efficacy of the two groups was compared. Results The therapeutic effect was 60.00% in observation group,and clinical benefit rate was 88.89%, which was higher than that of the control group treatment efficiency 20.00%. The clinical benefit rate was 66.67%, the difference was statistically significant（P0.05）. In the observation group, the incidence was 35.04%, which was lower than that of the control group 51.11%, the difference was statistically significant（P0.05）. Conclusion Compared with single chemotherapy, CIK cells combined with chemotherapy in patients with metastatic breast cancer is ideal, and the drug safety is relatively high.

关 键 词：CIK细胞 化疗 转移性乳腺癌 临床疗效 安全性 

分 类 号：R737.9[医药卫生—肿瘤]